Previous 10 | Next 10 |
Introduction to the Positive/Negative Forensic Value Stock Selections This quantitative study continues a series of multi-year test of the top three forensic algorithms used to detect bankruptcy risk, earnings manipulation, and financial irregularities. My forward testing compiles portfolio ...
Quick Take Rapt Therapeutics ( RAPT ) has filed to raise gross proceeds of $75 million from a U.S. IPO, according to an S-1/A registration statement . The firm is focused on developing small-molecule drugs for patients with high unmet clinical needs in oncological and inflammatory disease...
AnaptysBio ( ANAB ) stock closed lower by 11% on Friday after a rival drug known as REGN3500 from Regeneron Pharmaceuticals ( REGN ) and its partner Sanofi ( SNY ), failed a mid-stage study in asthma . I believe that despite a rival failing with a similar drug, AnaptysBio's stock should...
Update with more details on stock movement and downgrade: More news on: AnaptysBio, Inc., Healthcare stocks news, Stocks on the move, Read more ...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Ole Andreas Halvorsen...
Thinly traded AnaptysBio ( ANAB +2.3% ) is up on below-average volume on the heels of updated results from a proof-of-concept Phase 2b clinical trial evaluating a single intravenous dose of lead candidate etokimab in 25 adults with severe eosinophilic asthma. The data were presented at E...
Single dose of etokimab resulted in rapid and sustained lung function improvement and ACQ-5 score reduction through at least Day 64 Etokimab was well tolerated and no serious adverse events were reported Data supports infrequent dosing of etokimab in the treatment of eosinophilic asthma...
Introduction to the Positive/Negative Forensic Value Stock Selections This quantitative study continues a series of multi-year test of the top three forensic algorithms used to detect bankruptcy risk, earnings manipulation, and financial irregularities. My forward testing compiles portfolio ...
SAN DIEGO, May 28, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio, ...
AnaptysBio (NASDAQ: ANAB ): Q1 GAAP EPS of -$0.82 beats by $0.01 . More news on: AnaptysBio, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States 60 Degrees Pharmaceuticals Inc. (SXTP) rose 98.3% to $0.4878 on volume of 116,444,604 shares NVIDIA Corporation (NVDA) fell 0.2% to $120.8 on volume of 26,900,560 shares Serve Robotics Inc. (SERV) rose 61.2% to $4.2399 on volume of 25...
2024-05-10 18:15:02 ET Wells Fargo analyst issues BUY recommendation for ANAB on May 10, 2024 05:01PM ET. The previous analyst recommendation was Buy. ANAB was trading at $23.41 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current ana...
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colit...